For investors aiming to assemble a portfolio of lasting, superior businesses, the quality investing method gives a structured system. This approach centers on finding companies with durable competitive strengths, sound financial condition, and a demonstrated history of producing high returns on capital over many years. The "Caviar Cruise" stock screen puts this thinking into practice by selecting for firms with steady revenue and profit increases, high returns on invested capital, strong free cash flow production, and reasonable debt. A company that clears this strict screen deserves more attention from investors who value long-term business strength over near-term market changes.
One company that results from this quality-centered screen is Exelixis Inc. (NASDAQ:EXEL), a biopharmaceutical company focused on oncology. Exelixis’s main product, cabozantinib, is approved for multiple hard-to-treat cancers, forming a base for the company's financial results. A review of the main Caviar Cruise criteria shows why Exelixis is notable as a possible choice for quality-focused portfolios.
Matching the Central Quality Standards
The Caviar Cruise screen rests on measurable foundations of business strength. Exelixis not only matches but frequently greatly surpasses these minimum needs, as shown by the given numbers.
- High Profitability and Capital Use: A key part of quality investing is a high Return on Invested Capital (ROIC), which gauges how well a company produces profits from its capital. The screen asks for an ROIC (leaving out cash, goodwill, and intangibles) over 15%. Exelixis states a notable ROICexgc of 54.14%, reflecting outstanding efficiency and a strong economic position around its cancer treatments.
- Strong Earnings Increase: The screen requires that a company's Earnings Before Interest and Taxes (EBIT) increase more quickly than its revenue over five years, pointing to better profitability and possible pricing strength. Exelixis shows this plainly:
- Revenue Growth (5Y CAGR): 7.52%
- EBIT Growth (5Y CAGR): 51.98% This large difference indicates the company's effective shift to profitability and expandable operations as its commercial products became established.
- Notable Financial Condition and Cash Flow: Quality companies are defined by solid balance sheets and the skill to turn accounting profits into actual cash. The screen selects for a Debt/Free Cash Flow ratio below 5 and an average Profit Quality above 75% for the last five years.
- Exelixis has a Debt/FCF ratio of 0.0, meaning it carries no net debt. This gives great financial room and stability.
- Its average Profit Quality (5Y) is 142.21%, well above the 75% mark. This means the company is producing much more free cash flow than its stated net income, a sign of a strong, cash-producing business.
Foundational Strength Outside the Screen
A detailed fundamental analysis report for Exelixis supports the image shown by the screen numbers. The report gives EXEL a high total fundamental score of 8 out of 10, noting strong points in two important areas:
- Profitability (Score: 9/10): The company scores very well on profitability measures, with sector-leading margins. Its Operating Margin of 38.48% and Profit Margin of 33.73% do better than most of its biotechnology competitors. The report also mentions steady gain in these margins in recent years.
- Financial Condition (Score: 9/10): The balance sheet is a definite asset. With no debt and a large cash holding, the company's solvency is very secure. The report affirms that Exelixis is "creating value," as its ROIC is much higher than its cost of capital.
The valuation score of 8 implies the stock could be fairly valued, particularly compared to its own high profitability and the wider market. While future growth projections are more measured than its fast past growth, the company's settled commercial base and research pipeline give a footing for ongoing progress.
A Quality Investing Possibility
For the quality investor, Exelixis offers a strong case. It works in the stable oncology field, meeting ongoing medical needs, a trait that fits the quality investing liking for businesses connected to long-term directions. Its absence of debt, exceptional cash conversion, and top-tier returns on capital show careful management and a firm competitive standing in its area. While the biotech sector has natural pipeline and patent-linked risks, Exelixis’s present financial traits are those of an established, high-caliber business instead of a speculative early-stage company.
The Caviar Cruise screen is made to find companies with these lasting qualities. Exelixis’s results against the screen's particular financial filters build a solid argument for its place on a quality investor's study list.
Interested in examining other companies that clear the Caviar Cruise quality screen? You can locate and adjust the screen for your own study here.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer or solicitation to buy or sell any securities. The information presented is based on data provided and should not be the sole basis for any investment decision. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment.